Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Sold by Hara Capital LLC

Hara Capital LLC trimmed its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 7.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 30,380 shares of the company’s stock after selling 2,400 shares during the quarter. Hara Capital LLC’s holdings in Teva Pharmaceutical Industries were worth $670,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its position in Teva Pharmaceutical Industries by 49.5% in the third quarter. FMR LLC now owns 62,740,763 shares of the company’s stock worth $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd lifted its position in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after acquiring an additional 2,204,623 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. lifted its position in shares of Teva Pharmaceutical Industries by 2.2% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock valued at $573,822,000 after acquiring an additional 569,412 shares during the last quarter. State Street Corp lifted its position in shares of Teva Pharmaceutical Industries by 10.0% during the 3rd quarter. State Street Corp now owns 19,500,683 shares of the company’s stock valued at $351,402,000 after acquiring an additional 1,778,268 shares during the last quarter. Finally, AustralianSuper Pty Ltd lifted its position in shares of Teva Pharmaceutical Industries by 16.8% during the 4th quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company’s stock valued at $203,268,000 after acquiring an additional 1,329,319 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $16.24 on Tuesday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.61. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company’s fifty day moving average price is $19.93 and its two-hundred day moving average price is $18.50.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.62 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Roberto Mignone sold 286,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on TEVA. JPMorgan Chase & Co. increased their price objective on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a report on Thursday, January 30th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays reduced their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries currently has an average rating of “Moderate Buy” and an average target price of $23.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.